IP Library Granted Patent US 11,026,953
Granted Patent B2
US 11,026,953 · App. 16/484,920 · Granted Jun 8, 2021

3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor

Inventors: Torbjörn Bäckström (Umeå, SE); Markus Jerling (Bromma, SE)
Assignee: ASARINA PHARMA AB
A61K31/57A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,026,953
App. No.
16/484,920
Granted
Jun 8, 2021
Kind
B2
Abstract

The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.

Claims (7)

1. A method of treating essential tremor in a patient, comprising administering an effective amount of 3beta-hydroxy-5alpha-pregnan-20-one, to the patient.

2. The method of claim 1 , wherein the 3beta-hydroxy-5alpha-pregnan-20-one-is administered in combination with at least one additional active compound, selected from the group consisting of primidone, topiramate, phenobarbital, propranolol, atenolol, nadolol, metoprolol, timolol, R-baclofen, clonazepam, gabapentin, pregabalin, nimodipine, clozapine, olanzapine, and botulinim toxin A.

3. The method of claim 1 , further comprising the step of administering deep brain stimulation to the patient.

4. The method of claim 2 , further comprising the step of administering deep brain stimulation to the patient.

5. The method of claim 1 , wherein the 3beta-hydroxy-5alpha-pregnan-20-one is in the form of a pharmaceutically acceptable ester.

6. The method according to claim 1 , wherein said 3beta-hydroxy-5-alpha-pregnan-20-one is administered intravenously, nasally, buccally, vaginally, rectally, subcutaneously, percutaneously or orally.

7. The method according to claim 1 , wherein said 3beta-hydroxy-5-alpha-pregnan-20-one is administered topically, locally, orally, parenterally or pulmonary.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2025
From: ASARINA PHARMA AB
To: RELMADA THERAPEUTICS, INC.
Reel/Frame 070543/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2019
From: BÄCKSTRÖM, TORBJÖRN; JERLING, MARKUS
To: ASARINA PHARMA AB
Reel/Frame 050470/0710 →
Priority Claims (1)
SE 1750124-8 · Feb 10, 2017 · national
Continuity (1)
Related Publication 20190381069A1 · Dec 19, 2019